AMREEN AZIZ: Open Payments
NPI 1750701173 · FREDERICK, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,893 in 95 payments from 23 companies in 2025. Trend: 2023 $1,778 · 2024 $2,023 · 2025 $1,893
Food & beverage: $1,893
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $277 |
| AstraZeneca Pharmaceuticals LP | 10 | $215 |
| Amgen Inc. | 13 | $214 |
| Novo Nordisk Inc | 8 | $182 |
| Lilly USA, LLC | 7 | $135 |
| GlaxoSmithKline, LLC. | 6 | $133 |
| Abbott Laboratories | 5 | $104 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $88 |
| PFIZER INC. | 3 | $61 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $59 |
Products named: AIRSUPRA, TRELEGY ELLIPTA, QULIPTA, EVENITY, FREESTYLE LIBRE 3, Ozempic, VRAYLAR, CAPLYTA.
Industry payments across MD — which companies pay providers there.
